Do Defects in the Innate Immune System Contribute to Non-Cystic Fibrosis Bronchiectasis in Maori and Pacific Island Children?

In Maori and Pacific Island children with Non-Cystic Fibrosis Bronchiectasis, will measurement of CD62 Ligand shedding detect defects of the innate immune system?

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613001164785

Enrollment

100

Registered

2013-10-21

Start date

2014-01-07

Completion date

2014-08-31

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Bronchiectasis is an abnormal and irreversible dilatation of the bronchi or breathing tubes, leading to chronic cough, chest infections and breathing difficulties. It is common and severe in New Zealand with a prevalence of 1/3000 overall, but 1/1200 Maori and 1/650 Pacifica children. The cause is unknown in the majority of cases. Our clinical suspicion is that there is more than just social determinants placing these children at risk. The innate immune system provides the first line of defence against infection. Toll-like receptors (TLR) are part of the innate immune system that recognise pathogens, and it is possible to screen for problems with TLR by measuring the shedding of a protein called CD62 Ligand from cells. Our hypothesis is that defects in the Toll-like Receptor pathway of the innate immune system contribute to high rates of bronchiectasis in Maori and Pacifica children. Identification of a genetic predisposition to defects in the innate immune system would enable us to identify children at risk of bronchiectasis and intensify early prevention and treatment measures in order to reduce health inequalities.

Interventions

Measurement of CD62 Ligand shedding using flow cytometry to screen for defects in the Toll-like Receptor pathway of the innate immune system in Maori and Pacifica children with bronchiectasis. Participants will have CD62 Ligand shedding measured once only. Time to results is 2 hours. The total duration of the trial is 1 year with no follow up period.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Diagnosis

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

0 to 15 Years

Healthy volunteers

Yes

Inclusion criteria

Bronchiectasis group: <15 years old at time of enrolment, Maori or Pacifica, confirmed bronchiectasis on HRCT scan, clinical diagnosis by respiratory physician, consent to study. Healthy control group: <15 years old at time of enrolment, Maori or Pacifica, consent to study.

Exclusion criteria

Bronchiectasis group: Cystic fibrosis not excluded as diagnosis, known primary immunodeficiency, primary ciliary dyskinesia, non-consent to study. Healthy control group: Infectious comorbidities, history of recurrent infections or Rheumatic Fever, non-consent

Outcome results